Immunotherapeutic applications of IL-15

Immunotherapy

Volumn 4, Issue 9, 2012, Pages 957-969

  Croce, Michela ^a   Orengo, Anna Maria ^a   Azzarone, Bruno ^b,c   Ferrini, Silvano ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b HÔPITAL PAUL BROUSSE   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

cancer immunotherapy; HIV infection; IL 15; IL 15R ; lymphoid neoplasia

Indexed keywords

CD40 LIGAND; DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS GAG DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 15 RECEPTOR ALPHA; INTERLEUKIN 2; INTERLEUKIN 7; KEYHOLE LIMPET HEMOCYANIN; LIPOPOLYSACCHARIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PENNVAX B; RECOMBINANT INTERLEUKIN 15; SIGNAL PEPTIDE; STAT5 PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADOPTIVE TRANSFER; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; B CELL LEUKEMIA; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CARCINOMA; CD4 LYMPHOCYTE COUNT; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SURVIVAL; CHILDHOOD CANCER; CHROMOSOME 7; CLINICAL STUDY; CUTANEOUS T CELL LYMPHOMA; CYTOKINE RELEASE; DENDRITIC CELL; DRUG SCREENING; FOLLICULAR LYMPHOMA; GENE MAPPING; HAPLOIDY; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOTOXICITY; KIDNEY CANCER; LYMPHOMA; MELANOMA; METASTATIC MELANOMA; NATURAL KILLER CELL; NEUTROPENIA; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REGULATORY MECHANISM; REVIEW; RHESUS MONKEY; SKIN CANCER; T CELL LEUKEMIA; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR XENOGRAFT; VACCINATION; VASCULAR DISEASE; VASCULAR LEAK SYNDROME;

ANIMALS; CLINICAL TRIALS AS TOPIC; HIV INFECTIONS; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-15; NEOPLASMS;

EID: 84867342693     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.12.92     Document Type: Review

References (97)

1. Rochman Y, Spolski R, Leonard WJ. New insights into the regulation of T cells by gamma(c) family cytokines. Nat. Rev. Immunol. 9, 480-490 (2009).
2. Meazza R, Azzarone B, Orengo AM, Ferrini S. Role of common-gamma chain cytokines in cell development and function: perspectives for immunotherapy. J. Biomed. Biotechnol. 2011, 861920 (2011).
3. Casanova JL, Holland SM, Notarangelo LD. Inborn errors of human JAKs and STATs. Immunity 36, 515-528 (2012).
4. Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. Immunol. Rev. 228, 273-287 (2009).
5. Grabstein KH, Eisenman J, Shanebeck JK et al. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 264, 965-968 (1994). (Pubitemid 24196167)
6. Carson WE, Giri JG, Lindemann MJ et al. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J. Exp. Med. 180, 1395-1403 (1994). (Pubitemid 24289613)
7. Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat. Rev. Immunol. 6, 595-601 (2006). (Pubitemid 44134092)
8. Kennedy MK, Glaccum M, Brown SN et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J. Exp. Med. 191, 771-780 (2000).
9. Meazza R, Verdiani S, Biassoni R et al. Identification of a novel interleukin-15 (IL-15) transcript isoform generated by alternative splicing in human small cell lung cancer cell lines. Oncogene 12, 2187-2192 (1996). (Pubitemid 26000142)
10. Gaggero A, Azzarone B, Andrei C et al. Differential intracellular trafficking, secretion and endosomal localization of two IL-15 isoforms. Eur. J. Immunol. 29, 1265-1274 (1999). (Pubitemid 29164173)
11. Kurys G, Tagaya Y, Bamford R, Hanover JA, Waldmann TA. The long signal peptide isoform and its alternative processing direct the intracellular trafficking of interleukin-15. J. Biol. Chem. 275, 30653-30659 (2000).
12. Anderson DM, Kumaki S, Ahdieh M et al. Functional characterization of the human interleukin-15 receptor alpha chain and close linkage of IL15RA and IL2RA genes. J. Biol. Chem. 270, 29862-29869 (1995). (Pubitemid 26002153)
13. Stonier SW, Schluns KS. Trans-presentation: a novel mechanism regulating IL-15 delivery and responses. Immunol. Lett. 127, 85-92 (2010).
14. Dubois S, Mariner J, Waldmann TA, Tagaya Y. IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity 17, 537-547 (2002). (Pubitemid 35351500)
15. Koka R, Burkett PR, Chien M et al. Interleukin (IL)-15R(alpha)-deficient natural killer cells survive in normal but not IL-15R(alpha)-deficient mice. J. Exp. Med. 197, 977-984 (2003). (Pubitemid 36523195)
16. Lodolce JP, Burkett PR, Boone DL, Chien M, Ma A. T cell-independent interleukin 15Ralpha signals are required for bystander proliferation. J. Exp. Med. 194, 1187-1194 (2001).
17. Chenoweth MJ, Mian MF, Barra NG. IL-15 can signal via IL-15Ra, J, and NF-kB to drive RANTES production by myeloid cells. J. Immunol. 188, 4149-4157 (2012).
18. Barzegar C, Meazza R, Pereno R et al. IL-15 is produced by a subset of human melanomas, and is involved in the regulation of markers of melanoma progression through juxtacrine loops. Oncogene 16, 2503-2512 (1998). (Pubitemid 28258582)
19. Musso T, Calosso L, Zucca M et al. Human monocytes constitutively express membrane-bound, biologically active, and interferon-gamma-upregulated interleukin-15. Blood 93, 3531-3539 (1999). (Pubitemid 29220921)
20. Giron-Michel J, Giuliani M, Fogli M et al. Membrane-bound and soluble IL-15/IL-15Ralpha complexes display differential signaling and functions on human hematopoietic progenitors. Blood 106, 2302-2310 (2005). (Pubitemid 41510800)
21. Mortier E, Woo T, Advincula R, Gozalo S, Ma A. IL-15Ralpha chaperones IL-15 to stable dendritic cell membrane complexes that activate cells via trans presentation. J. Exp. Med. 205, 1213-1225 (2008). (Pubitemid 351679694)
22. Huntington ND, Legrand N, Alves NL et al. IL-15 trans-presentation promotes human cell development and differentiation in vivo. J. Exp. Med. 206, 25-34 (2009).
23. Bulfone-Paus S, Bulanova E, Budagian V, Paus R. The interleukin-15/ interleukin-15 receptor system as a model for juxtacrine and reverse signaling. Bioessays 28, 362-377 (2006).
24. Neely GG, Epelman S, Ma LL et al. Monocyte surface-bound IL-15 can function as an activating receptor and participate in reverse signaling. J. Immunol. 172, 4225-4234 (2004). (Pubitemid 38375235)
25. Khawam K, Giron-Michel J, Gu Y et al. Human renal cancer cells express a novel membrane-bound interleukin-15 that induces, in response to the soluble interleukin-15 receptor alpha chain, epithelial-to-mesenchymal transition. Cancer Res. 69, 1561-1569 (2009).
26. Mackiewicz A, Schooltink H, Heinrich PC, Rose-John S. Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins. J. Immunol. 149, 2021-2027 (1992).
27. Mortier E, Quéméner A, Vusio P et al. Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins. J. Biol. Chem. 281, 1612-1619 (2006).
28. Fehniger TA, Cai SF, Cao X et al. Acquisition of murine cell cytotoxicity requires the translation of a pre-existing pool of granzyme B and perforin mRNAs. Immunity 26, 798-811 (2007). (Pubitemid 46907665)
29. Fehniger TA, Shah MH, Turner MJ et al. Differential cytokine and chemokine gene expression by human cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J. Immunol. 162, 4511-4520 (1999). (Pubitemid 29314849)
30. Huntington ND, Puthalakath H, Gunn P et al. Interleukin 15-mediated survival of natural killer cells is determined by interactions among Bim, Noxa and Mcl-1. Nat. Immunol. 8, 856-863 (2007). (Pubitemid 47103041)
31. Rosmaraki EE, Douagi I, Roth C, Colucci F, Cumano A, Di Santo JP. Identification of committed cell progenitors in adult murine bone marrow. Eur. J. Immunol. 31, 1900-1909 (2001). (Pubitemid 32547352)
32. Freud AG, Yokohama A, Becknell B. Evidence for discrete stages of human natural killer cell differentiation in vivo. J. Exp. Med. 203, 1033-1043 (2006).
33. Grzywacz B, Kataria N, Kataria N, Blazar BR, Miller JS, Verneris MR. Natural killer-cell differentiation by myeloid progenitors. Blood 117, 3548-3558 (2011).
34. Perez SA, Sotiropoulou PA, Gkika DG et al. A novel myeloid-like cell progenitor in human umbilical cord blood. Blood 101, 3444-3450 (2003). (Pubitemid 36857927)
35. Vosshenrich CA, Ranson T, Samson SI et al. Roles for common cytokine receptor gamma-chain-dependent cytokines in the generation, differentiation, and maturation of cell precursors and peripheral cells in vivo. J. Immunol. 174, 1213-1221 (2005).
36. Moretta L, Ferlazzo G, Bottino C et al. Effector and regulatory events during natural killer-dendritic cell interactions. Immunol. Rev. 214, 219-228 (2006). (Pubitemid 44707913)
37. Ferlazzo G, Pack M, Thomas D et al. Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. Proc. Natl Acad. Sci. USA 101, 16606-16611 (2004). (Pubitemid 39557760)
38. Morandi B, Mortara L, Carrega P et al. Cells provide helper signal for CD8+ T cells by inducing the expression of membrane-bound IL-15 on DCs. Int. Immunol. 21, 599-606 (2009).
39. Lucas M, Schachterle W, Oberle K, Aichele P, Diefenbach A. Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity 26, 503-517 (2007). (Pubitemid 46602996)
40. Perera PY, Lichy JH, Waldmann TA, Perera LP. The role of interleukin-15 in inflammation and immune responses to infection: implications for its therapeutic use. Microbes Infect. 14, 247-261 (2012).
41. Banchereau J, Thompson-Snipes L, Zurawski S et al. The differential production of cytokines by human Langerhans cells and dermal CD14+ DCs controls CTL priming. Blood 119(24), 5742-5749 (2012).
42. Wong JL, Mailliard RB, Moschos SJ et al. Helper activity of natural killer cells during the dendritic cell-mediated induction of melanoma-specific cytotoxic T cells. J. Immunother. 34, 270-278 (2011).
43. Park CS, Yoon SO, Armitage RJ, Choi YS. Follicular dendritic cells produce IL-15 that enhances germinal center B cell proliferation in membrane-bound form. J. Immunol. 173, 6676-6683 (2004). (Pubitemid 39541052)
44. McDonald PP, Russo MP, Ferrini S, Cassatella MA. Interleukin-15 (IL-15) induces NF-kappaB activation and IL-8 production in human neutrophils. Blood 92, 4828-4835 (1998). (Pubitemid 29005886)
45. Pelletier M, Ratthé C, Girard D. Mechanisms involved in interleukin-15-induced suppression of human neutrophil apoptosis: role of the anti-apoptotic Mcl-1 protein and several kinases including Janus kinase-2, p38 mitogen-activated protein kinase and extracellular signal-regulated kinases-1/2. FEBS Lett. 532, 164-170 (2002). (Pubitemid 35375883)
46. Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat. Rev. Immunol. 4, 665-674 (2004). (Pubitemid 39223073)
47. Fewkes NM, Mackall CL. Novel gamma-chain cytokines as candidate immune modulators in immune therapies for cancer. Cancer J. 16, 392-398 (2010).
48. Jakobisiak M, Golab J, Lasek W. Interleukin 15 as a promising candidate for tumor immunotherapy. Cytokine Growth Factor Rev. 22, 99-108 (2011).
49. Steel JC, Waldmann TA, Morris JC. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol. Sci. 33, 35-41 (2012).
50. Munger W, DeJoy SQ, Jeyaseelan R et al. Studies evaluating the antitumor activity and toxicity of interleukin-15, a new T cell growth factor: comparison with interleukin-2. Cell. Immunol. 165, 289-293 (1995).
51. Meazza R, Lollini PL, Nanni P et al. Gene transfer of a secretable form of IL-15 in murine adenocarcinoma cells: effects on tumorigenicity, metastatic potential and immune response. Int. J. Cancer 87, 574-581 (2000). (Pubitemid 30639819)
52. Di Carlo E, Comes A, Basso S et al. The combined action of IL-15 and IL-12 gene transfer can induce tumor cell rejection without T and NK cell involvement. J. Immunol. 165, 3111-3118 (2000).
53. Orengo AM, Di Carlo E, Comes A et al. Tumor cells engineered with IL-12 and IL-15 genes induce protective antibody responses in nude mice. J. Immunol. 171, 569-575 (2003). (Pubitemid 36871363)
54. Croce M, Meazza R, Orengo AM et al. Sequential immunogene therapy with interleukin-12-and interleukin-15-engineered neuroblastoma cells cures metastatic disease in syngeneic mice. Clin. Cancer Res. 11, 735-742 (2005). (Pubitemid 40116902)
55. Lasek W, Basak G, Switaj T et al. Complete tumour regressions induced by vaccination with IL-12 gene-transduced tumour cells in combination with IL-15 in a melanoma model in mice. Cancer Immunol. Immunother. 53, 363-372 (2004). (Pubitemid 38392314)
56. Comes A, Di Carlo E, Musiani P et al. IFN-gamma-independent synergistic effects of IL-12 and IL-15 induce anti-tumor immune responses in syngeneic mice. Eur. J. Immunol. 32, 1914-1923 (2002). (Pubitemid 34814547)
57. Zhang M, Yao Z, Dubois S, Ju W, Müller JR, Waldmann TA. Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer. Proc. Natl Acad. Sci. USA 106, 7513-7518 (2009).
58. Yu P, Steel JC, Zhang M, Morris JC, Waldmann TA. Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model. Clin. Cancer Res. 16, 6019-6028 (2010).
59. Yu P, Steel JC, Zhang M et al. Simultaneous inhibition of two regulatory T-cell subsets enhanced interleukin-15 efficacy in a prostate tumor model. Proc. Natl Acad. Sci. USA 109, 6187-6192 (2012).
60. Kermer V, Baum V, Hornig N et al. An antibody fusion protein for cancer immunotherapy mimicking IL-15 trans-presentation at the tumor site. Mol. Cancer Ther. 11(6), 1279-1288 (2012).
61. Dubsky P, Saito H, Leogier M et al. IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL. Eur. J. Immunol. 37, 1678-1690 (2007). (Pubitemid 46939501)
62. Steel JC, Ramlogan CA, Yu P et al. Interleukin-15 and its receptor augment dendritic cell vaccination against the neu oncogene through the induction of antibodies partially independent of CD4 help. Cancer Res. 70, 1072-1081 (2010).
63. Stephenson KB, Barra NG, Davies E, Ashkar AA, Lichty BD. Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-tumor immunity. Cancer Gene Ther. 19, 238-246 (2012).
64. Locatelli F, Pende D, Maccario R et al. Haploidentical hemopoietic stem cell transplantation for the treatment of high-risk leukemias: how cells make the difference. Clin. Immunol. 133, 171-178 (2009).
65. Fujisaki H, Kakuda H, Shimasaki N et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res. 69, 4010-4017 (2009).
66. Shook DR, Campana D. Natural killer cell engineering for cellular therapy of cancer. Tissue Antigens 78, 409-415 (2011).
67. De Maria A, Moretta L. Cell function in HIV-1 infection. Curr. HIV Res. 6, 433-440 (2008).
68. Alter G, Altfeld M. Mutiny or scrutiny: cell modulation of DC function in HIV-1 infection. Trends Immunol. 32, 219-224 (2011).
69. Keating SM, Golub ET, Nowicki M et al. The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of women. AIDS 25(15), 1823-1832 (2011).
70. d'Ettorre G, Forcina G, Lichtner M et al. Interleukin-15 in HIV infection: immunological and virological interactions in antiretroviral-naive and-treated patients. AIDS 16, 181-188 (2002). (Pubitemid 34118564)
71. d'Ettorre G, Andreotti M, Ceccarelli G et al. The role of IL-15 in challenging Acquired Immunodeficiency Syndrome. Cytokine 57, 54-60 (2012).
72. Mueller YM, Bojczuk PM, Halstead ES et al. IL-15 enhances survival and function of HIV-specific CD8+ T cells. Blood 101, 1024-1029 (2003). (Pubitemid 36139375)
73. Pacheco Y, Solé V, Billaud E et al. Despite an impaired response to IL-7, CD4+EM T cells from HIV-positive patients proliferate normally in response to IL-15 and its superagonist, RLI. AIDS 25, 1701-1710 (2011).
74. Sui Y, Gagnon S, Dzutsev A et al. TLR agonists and/or IL-15 adjuvanted mucosal SIV vaccine reduced gut CD4+ memory T cell loss in SIVmac251-challenged rhesus macaques. Vaccine 30, 59-68 (2011).
75. Li S, Qi X, Gao Y et al. IL-15 increases the frequency of effector memory CD8+ T cells in rhesus monkeys immunized with HIV vaccine. Cell. Mol. Immunol. 7, 491-494 (2010).
76. Dubie RA, Maksaereekul S, Shacklett BL et al. Co-immunization with IL-15 enhances cellular immune responses induced by a vif-deleted simian immunodeficiency virus proviral DNA vaccine and confers partial protection against vaginal challenge with SIVmac251. Virology 386, 109-121 (2009).
77. Valentin A, von Gegerfelt A, Rosati M et al. Repeated DNA therapeutic vaccination of chronically SIV-infected macaques provides additional virological benefit. Vaccine 28, 1962-1974 (2010).
78. Berger C, Berger M, Hackman RC et al. Safety and immunologic effects of IL-15 administration in nonhuman primates. Blood 114, 2417-2426 (2009).
79. Waldmann TA, Lugli E, Roederer M et al. Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood 117, 4787-4795 (2011).
80. de Totero D, Meazza R, Capaia M et al. The opposite effects of IL-15 and IL-21 on CLL B cells correlate with differential activation of the JAK/STAT and ERK1/2 pathways. Blood 111, 517-524 (2008).
81. Epron G, Ame-Thomas P, Le Priol J et al. Monocytes and T cells cooperate to favor normal and follicular lymphoma B-cell growth role of IL-15 and CD40L signaling. Leukemia 26, 139-148 (2012).
82. Leroy S, Dubois S, Tenaud I et al. Interleukin-15 expression in cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome). Br. J. Dermatol. 144, 1016-1023 (2001). (Pubitemid 34203355)
83. Mariner JM, Lantz V, Waldmann TA, Azimi N. Human T cell lymphotropic virus type I Tax activates IL-15R alpha gene expression through an NF-kappa B site. J. Immunol. 166, 2602-2609 (2001). (Pubitemid 32173498)
84. Fehniger TA, Suzuki K, Ponnappan A et al. Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells. J. Exp. Med. 193, 219-231 (2001). (Pubitemid 32524453)
85. Zambello R, Facco M, Trentin L et al. Interleukin-15 triggers the proliferation and cytotoxicity of granular lymphocytes in patients with lymphoproliferative disease of granular lymphocytes. Blood 89, 201-211 (1997). (Pubitemid 26428194)
86. Ju W, Zhang M, Jiang JK et al. CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP. Blood 117, 1938-1946 (2011).
87. Gangemi R, Paleari L, Orengo AM et al. Cancer stem cells: a new paradigm for understanding tumor growth and progression and drug resistance. Curr. Med. Chem. 16, 1688-1703 (2009).
88. Azzi S, Bruno S, Giron-Michel J et al. Differentiation therapy: targeting human renal cancer stem cells with interleukin 15. J. Natl Cancer Inst. 103, 1884-1898 (2011).
89. Kedzierska K, Crowe SM. Cytokines and HIV-1: interactions and clinical implications. Antivir. Chem. Chemother. 12, 133-150 (2001). (Pubitemid 32963913)
90. Eberly MD, Kader M, Hassan W et al. Increased IL-15 production is associated with higher susceptibility of memory CD4 T cells to simian immunodeficiency virus during acute infection. J. Immunol. 182, 1439-1448 (2009).
91. Lugli E, Mueller YM, Lewis MG et al. IL-15 delays suppression and fails to promote immune reconstitution in virally suppressed chronically SIV-infected macaques. Blood 118, 2520-2529 (2011).
92. Turcotte S, Rosenberg SA. Immunotherapy for metastatic solid cancers. Adv. Surg. 45, 341-360 (2011).
93. Zanzi D, Stefanile R, Santagata S et al. IL-15 interferes with suppressive activity of intestinal regulatory T cells expanded in celiac disease. Am. J. Gastroenterol. 106, 1308-1317 (2011).
94. Ben Ahmed M, Belhadj Hmida N, Moes N et al. IL-15 renders conventional lymphocytes resistant to suppressive functions of regulatory T cells through activation of the phosphatidylinositol 3-kinase pathway. J. Immunol. 182, 6763-6770 (2009).
95. Kalams SA, Parker S, Jin X et al. Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults. PLoS ONE 7(1), e29231 (2012).
96. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
97. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012).